PHARMACOTHERAPY OF UNSTABLE ANGINA

被引:4
|
作者
PRISANT, LM [1 ]
VONDOHLEN, T [1 ]
ROGERS, W [1 ]
HOUGHTON, JL [1 ]
CARR, AA [1 ]
FRANK, MJ [1 ]
机构
[1] MED COLL GEORGIA, DEPT RADIOL, CARDIOL SECT, AUGUSTA, GA 30912 USA
来源
JOURNAL OF CLINICAL PHARMACOLOGY | 1992年 / 32卷 / 05期
关键词
D O I
10.1002/j.1552-4604.1992.tb03852.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
All patients with unstable angina should be admitted to a coronary or an intensive care unit. There should be an attempt to classify the patient according to the proposed Braunwald nomenclature. If the patient has a secondary cause for unstable angina (e.g., tachyarrhythmia, heart failure, fever, thyrotoxicosis, severe hypertension, hypoxia, unusual emotional stress, or anemia), this condition should be treated initially with therapy specific for that etiology. If the patient does not have a secondary etiology, therapy should be initiated with nitrates, preferably intravenous nitroglycerin. Heparin should be concomitantly administered. If the patient cannot receive heparin, aspirin should be initiated. All patients should receive β-blockers. If the patient cannot take a β-blocker, a calcium antagonist (probably diltiazem) should be initiated. However, if the patient is refractory to β-blockers, the dihydropyridine nifedipine should be added. Failure to all pharmacologic interventions necessitates a progressive invasive approach dictated by the potential surgical risk of the patient. Long-term aspirin and β-blockers should be strongly considered.
引用
收藏
页码:390 / 399
页数:10
相关论文
共 50 条